Movatterモバイル変換


[0]ホーム

URL:


CN101991538A - TPGS-containing liposome composition and application thereof - Google Patents

TPGS-containing liposome composition and application thereof
Download PDF

Info

Publication number
CN101991538A
CN101991538ACN2009101016078ACN200910101607ACN101991538ACN 101991538 ACN101991538 ACN 101991538ACN 2009101016078 ACN2009101016078 ACN 2009101016078ACN 200910101607 ACN200910101607 ACN 200910101607ACN 101991538 ACN101991538 ACN 101991538A
Authority
CN
China
Prior art keywords
tpgs
liposome
medicine
cholesterol
liposome composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN2009101016078A
Other languages
Chinese (zh)
Other versions
CN101991538B (en
Inventor
熊素彬
R·J·李
尹小东
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zhejiang University of Technology ZJUT
Original Assignee
Zhejiang University of Technology ZJUT
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zhejiang University of Technology ZJUTfiledCriticalZhejiang University of Technology ZJUT
Priority to CN2009101016078ApriorityCriticalpatent/CN101991538B/en
Publication of CN101991538ApublicationCriticalpatent/CN101991538A/en
Application grantedgrantedCritical
Publication of CN101991538BpublicationCriticalpatent/CN101991538B/en
Expired - Fee Relatedlegal-statusCriticalCurrent
Anticipated expirationlegal-statusCritical

Links

Images

Landscapes

Abstract

The invention discloses a tocopheryl polyethylene glycol succinate (TPGS)-containing liposome composition and application thereof. The liposome composition consists of a phospholipid compound, a cholesterol compound and TPGS. The weight ratio of the phospholipid compound to the cholesterol compound to the TPGS is 5 to 95:0 to 50:0.1 to 60. The TPGS-containing liposome composition is applied to preparing medicine-loading liposomes, can improve the stability of liposome medicaments and the curative effect of the medicaments.

Description

A kind of liposome composition and application thereof that contains TPGS
Technical field
The present invention relates to the liposome composition of a kind of TPGS of containing, and by its drug-loaded liposome for preparing.
Background technology
The bilayer structure of the similar cell membrane that liposome mainly is made up of phospholipid and cholesterol.Liposome can be divided three classes: little single chamber (layer) liposome, and particle diameter is 20~80nm; Large unilamellar vesicle, particle diameter is about 100~1000nm; Multicell (layer) liposome, particle diameter is about 1000~5000nm.Conventional liposome has been experienced in the development of liposome, and the PEG modified liposome is to receptor or ligand modified liposome.The liposome of clinical practice at present is mainly conventional liposome (as DaunoXome) and PEG modified liposome (as Doxil).Compare with conventional liposome, the PEG modified liposome has the particle diameter that reduces liposome, improves the stability of liposome, and the extension body circulation time improves advantages such as cancer therapy drug targeting.Liposome PEG dressing agent commonly used is mainly PEG (2000)-DSPE, modifies Evacet listing product Doxil as PEG; Still the surfactant that has some to contain PEG in addition, as Tween80, Poloxmer188, etc.
The preparation method of liposome has multiple, according to the character of medicine maybe needs select.(1) film dispersion method: be that film materials such as phospholipid are dissolved in an amount of chloroform or other organic solvent, fat-soluble medicine can be added in the organic solvent, under the decompression rotation, remove then and desolvate, make lipid after wall forms thin film, add the buffer solution or other solution that do not contain or contain water soluble drug, carry out jolting, then can form multilamellar liposome.(2) injection method: matrix materials such as phospholipid and fat-soluble medicine are dissolved in (oil phase) in the organic solvent, then the oil phase average rate are expelled in the water (containing or do not contain water soluble drug), eliminate the method that organic solvent obtains liposome.Difference according to solvent can be divided into ethanol or tert-butyl alcohol injection method and ether injection method etc.(3) reverse phase evaporation: be that matrix materials such as phospholipid are dissolved in organic solvent, in chloroform, mix with the buffer of pastille by a certain percentage again, emulsifying that the pressure reducing and steaming organic solvent can form liposome then.This method is suitable for water soluble drug, macromole active substance, and the liposome preparation as insulin etc. can improve envelop rate.Freeze-drying and fusion method are still arranged in addition.The 5 kinds of methods in front disperse formed liposome mostly to be multilamelar liposome, available various mechanical means further disperses, to reduce particle diameter and to form small unilamellar vesicle: a) the ultrasonic method big multilamellar liposome ultrasonoscope supersound process that will obtain, according to the ultransonic intensity of adopt and action time length obtain small unilamellar vesicle.B) the homogenize method big multilamellar liposome that will obtain becomes liposome than small particle diameter by tissue mashing machine or the homogenize of high pressure dispersing emulsification machine.C) under high pressure continuously by behind the poly-carbonic acid fibrous membrane of aperture 1.0-0.05 μ m, the size distribution of liposome is tending towards homogeneous to the squeezing and pressing method big multilamellar liposome that will obtain, and mostly is unilamelar liposome.
When the preparation drug-loaded liposome, according to the character of medicine, the mechanism difference of loading can be divided into " initiatively medicine carrying " and " passive medicine carrying " two big classes.So-called " passive medicine carrying ", promptly at first medicine is soluble in the aqueous phase or organic facies (fat-soluble medicine) in, prepare drug-loaded liposome by selected method for preparing lipidosome then.For fat-soluble, with the high medicine of immobilized artificial membrane affinity, " passive medicine carrying " method is comparatively suitable.So-called " initiatively medicine carrying " promptly carries out medicine carrying by the different ions or the chemical compound gradient of water inside and outside the liposome, mainly is applicable to amphiphatic medicine.Active loading method mainly comprises (1) pH gradient method; (2) ammonium sulphate gradient; (3) calcium acetate gradient method or other ion gradient methods.
Ammonium sulphate gradient promptly earlier is wrapped in water in the liposome with ammonium sulfate, then the ammonium sulfate of water outward of the method weeding of grease plastid by dialysis, gel chromatography or ultrafiltration.Because the difference of ion pair bilayer infiltration coefficient, (0.13cm/s) is higher for the amino molecule infiltration coefficient, can be diffused into outer aqueous phase very soon; H+Infiltration coefficient much smaller than amino molecule, make that water is acid in the liposome, form the pH gradient, gradient magnitude is by [NH4+] outer water/[NH4+] interior water relatively determines, makes the contrary ammonium sulphate gradient of medicine be written into liposome like this.Medicine enters behind the liposome and SO42-The sulfate that forms reduces the bilayer infiltration coefficient, thereby makes weakly basic drugs have very high envelop rate and have good stable.
The calcium acetate gradient method makes a large amount of protons be transported to the outside pH of generation gradient from liposome interior by the calcium acetate concentration gradient (inner concentration is higher than the outside) of the transmembrane movement generation of calcium acetate.The permeability parameters (6.6 * 10 of acetic acid-4Cms-1) compare Ca2+(2.5 * 10-11Cms-1) big 7 orders of magnitude, so Ca2+Seldom pass through bimolecular film and stay liposome interior, acetic acid molecule has then participated in the proton transhipment.The Concentraton gradient that the calcium acetate transmembrane movement produces (inner concentration is higher than the outside) causes a large amount of protons to produce the pH gradient to the outside from the internal forwarding of liposome, and the imbalance of pH is carried for bag and the gathering weak acidic drug provides high efficiency drive power.
Initiatively medicine carrying with the common feature of passive medicine carrying is: the inside and outside water of liposome or the drug level basically identical on the bimolecular tunic in loading process, the factor that determines its envelop rate be medicine with interior water volume, liposome number and the medicine fat of the composition of the active force of immobilized artificial membrane, film material, liposome than (medicine and immobilized artificial membrane material compare) etc.
Vitamin E polyethylene glycol succinic acid ester (TPGS) is the soluble derivative of the vitamin E that formed through esterification by vitamin e succinate and cetomacrogol 1000, comprises d-alpha-tocopherol succinic acid macrogol ester (d-TPGS) and dl-alpha-tocopherol succinic acid macrogol ester (dl-TPGS).Reports such as Youk are prepared into TPGS with vitamin E, has certain antitumaous effect (Youk HJ, et al.Enhanced anticancer efficacy ofa-tocopheryl succinate by conjugation with polyethylene glycol.JControl Rel, 2005,107:43-52.).Yamagata etc. discover that TPGS can suppress the effect of P-gp among the drug resistance breast cancer cell MDCK-II and significantly promotes the picked-up of anticarcinogen mitoxantrone, improve anticancer therapeutic (Yamagata T, et al.Effect of excipients on breastcancer resistance protein substrate uptake activity.J Control Rel, 2007,124:1-5).Report TPGS such as Zhao can promote modified with folic acid PLGA nanoparticle at the picked-up of tumor cell and the cytotoxicity of medicine (Zhao H, et al.Addition ofTPGS tofolate-conjugated polymer micelles for selective tumor targeting.JBiomed Mater Res A.2008, epub).Cao etc. form carrier micelle with amycin and TPGS by chemical bond, the free amycin half-life prolongs 4.5 times of (Cao N, et al.Doxorubicin conjugated to D-a-tocopheryl polyethylene glycol 1000succinate (TPGS): Conjugation chemistry, characterization, in vitro andin vivo evaluation.Biomaterials,2008,29:3856-65)。In addition, TPGS can promote Transdermal absorption (the Chen CH of medicine, et al.Simultaneous effects of tocopherylpolyethylene glycol succinate (TPGS) on local hair growth promotionand systemic absorption of topically applied minoxidil in a mouse model.Int J Pharm.2005,306 (1-2): 91-8.) and promote oral absorption (Mu L, the et al.Mixed micelles made of poly (ethyleneglycol)-phosphatidylethanolamine conjugate and d-alpha-tocopherylpolyethylene glycol 1000 succinate as pharmaceutical nanocarriers forcamptothecin.Int J Pharm.2005 306 (1-2): 142-9.) of medicine
In view of TPGS is a kind of multi-functional pharmaceutic adjuvant.The present invention is intended to utilize the PEG chain (molecular weight 1000) and the hydrophobic vitamin E chain of TPGS possess hydrophilic property, and the hydrophobic chain of vitamin E can insert the hydrophobic layer of liposome, to form the PEG modified liposome.Utilize simultaneously TPGS the effect of inhibition P-gp glycoprotein, promote characteristic such as cellular uptake and drug absorption and design the drug-loaded liposome prescription that contains TPGS.
Summary of the invention
First technical problem that the present invention will solve is to provide a kind of novel liposome composition that contains TPGS, and it can not only improve liposome medicament stability, and can improve the curative effect of medicine.
For solving the problems of the technologies described above, the present invention adopts following technical scheme:
A kind of liposome composition that contains TPGS is made up of phospholipids compounds, cholesterol chemical compound and TPGS, and the weight portion ratio phospholipids compounds of each component: cholesterol chemical compound: TPGS is 5~95: 0~50: 0.1~60.Wherein the expression of the weight portion lower limit " 0 " of cholesterol chemical compound can be substantially equal to zero, but is not 0.
The weight portion ratio phospholipids compounds of the preferred described component of the present invention: cholesterol chemical compound: TPGS is 50~90: 10~40: 1~40.
The weight portion ratio phospholipids compounds of further preferred described component: cholesterol chemical compound: TPGS is 60~90: 10~30: 5~30.
Phospholipids compounds of the present invention can be selected from following a kind of or several combination arbitrarily: phosphatidylcholine class (PC), PHOSPHATIDYL ETHANOLAMINE class (PE), phosphatidyl glycerol class (PG), Phosphatidylserine (PS) etc.Wherein phosphatidylcholine class (PC) comprises the phosphatidylcholine of natural origin, as Ovum Gallus domesticus Flavus lecithin (EPC), soybean lecithin (SPC), hydrogenated soya phosphatide phatidylcholine (HSPC), hydrogenated yolk lecithin (HEL), cuorin (HPC), cephalin (BPC) and heparin (LPC) etc.; Synthetic saturated phospholipid phatidylcholine is as two lauric acid phosphatidylcholines (DLPC), two myristic acid phosphatidylcholines (DMPC), two Palmic acid phosphatidylcholines (DPPC), distearyl acid phosphatidylcholine (DSPC) etc.; And synthetic unsaturated phosphatidylcholine is as two oleic acid phosphatidylcholines (DOPC) etc.PHOSPHATIDYL ETHANOLAMINE class (PE) comprises distearyl acid PHOSPHATIDYL ETHANOLAMINE (DSPE), two oleic acid PHOSPHATIDYL ETHANOLAMINE (DOPE) etc.Phosphatidyl glycerol class (PG) comprises distearyl acid phosphatidyl glycerol (DSPG), two myristoyl phospholipid glycerol (DMPG) etc.The preferred phosphatidylcholine class of phospholipids compounds of the present invention, more preferably following a kind of or any several combinations: HSPC, DPPC, DSPC, DMPC, EPC, SPC.
It is one of following that cholesterol chemical compound of the present invention can be selected from: cholesterol, Cholesteryl hemisuccinate (CHEMS), cholesterol sulfate sodium, DC-chol (3 β-[N-(N '; the N-dimethyl aminoethyl) amido formoxyl] cholesterol), be preferably cholesterol, CHEMS or DC-chol.
Second technical problem that the present invention will solve provides the application of liposome composition in the preparation drug-loaded liposome of the described TPGS of containing, and promptly by liposome composition and medication preparation drug-loaded liposome, this drug-loaded liposome can significantly improve the curative effect of medicine.
The medicine that the present invention is suitable for can be various types of medicines, can be divided into following a few class according to its solubility property: water solublity, amphiphilic, fat-soluble.Water soluble drug comprises: nucleic acid class, protide and micromolecular water soluble drug class such as cisplatin, carboplatin, fluorouracil, cantharidin, norcantharidin, oxymatrine etc.; Amphiphilic medicine comprises: weakly basic drugs example hydrochloric acid amycin, daunorubicin hydrochloride, mitoxantrone hydrochloride, vincristine sulfate, Arechin (Polfa), Farmorubine Hydrochloride etc., weak acidic drug such as prednisolone sodium succinate, Inflamase, dexamethasone sodium phosphate, hydrocortisone sodium succinate, diclofenac sodium, Urbason Solubile, Protophenicol (Proto)., betamethasone sodium phosphate etc.; Fat-soluble medicine comprises: emodin, chrysophanic acid, amphotericin B, paclitaxel, Docetaxel, vitamin C succinate, sodium L-ascorbate-2-phosphate, Vitamin E acetate, vitamin A palmitate, camptothecine, hydroxy camptothecin etc.Preferably in the preparation of drug-loaded liposome, the weight of described medicine is 1~40% of liposome composition weight in the present invention, and is preferred 1~30%, more preferably 1~20%.
The described medicine of the concrete recommendation of the present invention is an emodin.
The present invention is concrete to recommend described drug-loaded liposome to be made by following component: 48~87 parts of Ovum Gallus domesticus Flavus lecithins, 11~24 parts in cholesterol, 2~38 parts of TPGS, 5 parts of emodins.
Drug-loaded liposome of the present invention can adopt the conventional method preparation, can select voluntarily according to the character and the needs of medicine, such as using injection method, film dispersion method etc., the mode that is written into of medicine can adopt initiatively medicine carrying or passive medicine carrying, in general, fat-soluble medicine can adopt passive medicine carrying mode, and amphipathic medicine can adopt initiatively medicine carrying mode, and initiatively the medicine carrying mode can be selected ammonium sulphate gradient, calcium acetate gradient method etc. for use according to pharmaceutical properties.Water soluble drug both can adopt initiatively medicine carrying mode, also can adopt passive medicine carrying mode.
When medicine is amphiphilic weakly basic drugs, recommend to be prepared by the following method: phospholipids compounds, cholesterol and TPGS are dissolved in the ethanol or the tert-butyl alcohol, inject (NH fast4)2SO4In the aqueous solution, form multilamelar liposome, N2Be pressed through 200nm and 100nm polycarbonate membrane down successively, get unilamelar liposome.(NH in buffer ultrafiltration such as reuse aqueous sucrose solution or the phosphate displacement liposome disperse medium4)2SO4, inside and outside the formation liposome bimolecular filmDegree gets blank unilamelar liposome; Then that amphiphilic weakly basic drugs is soluble in water, add in the blank unilamelar liposome, under the 37-65 ℃ of water bath condition, medicine is at NH4+Enter the liposome medicine carrying under the effect of gradient, obtain drug-loaded liposome.
When medicine is amphiphilic weak acidic drug, recommend to be prepared by the following method: phospholipids compounds, cholesterol and TPGS are dissolved in the ethanol or the tert-butyl alcohol, inject the calcium acetate aqueous solution fast, form multilamelar liposome, N2Be pressed through 200nm and 100nm polycarbonate membrane down successively, get unilamelar liposome.Calcium acetate in buffer ultrafiltration such as reuse aqueous sucrose solution or the acetate displacement liposome disperse medium forms the inside and outside calcium ion concentration gradient of liposome bimolecular film, gets blank unilamelar liposome; Then that amphiphilic weak acidic drug is soluble in water, add in the blank unilamelar liposome, under the 37-65 ℃ of water bath condition, medicine enters the liposome medicine carrying under the effect of calcium ion concentration gradient, obtain drug-loaded liposome.
When medicine is fat-soluble medicine, described drug-loaded liposome recommends to adopt following method to be prepared: phospholipids compounds, cholesterol, TPGS and fat-soluble medicine are placed reactor, adding organic solvent (preferred alcohol and/or chloroform) dissolves, the decompression rotary evaporation forms thin film, add normal saline or glycerine water solution hydrated films and form multilamelar liposome, N2Be pressed through 200nm and 100nm polycarbonate membrane down successively, get the single chamber drug-loaded liposome.
When medicine is water soluble drug, described drug-loaded liposome recommends to adopt following method preparation: phospholipids compounds, cholesterol chemical compound and TPGS are placed reactor, adding organic solvent (preferred chloroform, dichloromethane, ethanol) dissolves, the decompression rotary evaporation forms thin film, add the normal saline hydrated films that contains water soluble drug and form multilamelar liposome, N2Be pressed through 200nm and 100nm polycarbonate membrane down successively, get the single chamber drug-loaded liposome.
The drug-loaded liposome that the present invention makes is applicable to drug administration by injection, oral administration, percutaneous drug delivery and other mode administration.
Compared with prior art, beneficial effect of the present invention is: the present invention utilizes the multifunctionality design PEG modified liposome of TPGS.Utilize the PEG chain (molecular weight 1000) and the hydrophobic vitamin E chain of TPGS possess hydrophilic property, the hydrophobic chain of vitamin E can insert the hydrophobic layer of liposome, to form the PEG modified liposome, improves liposome stability and has the circulation of prolong drug body.Utilize simultaneously TPGS suppress the P-gp glycoprotein effect, promote characteristic such as cellular uptake and drug absorption and design contain TPGS the drug-loaded liposome prescription to improve curative effect of medication.Compare with existing PEG2000-DSPE modified liposome, short, sterically hindered little than the PEG chain of PEG2000-DSPE (PEG molecular weight 2000) because of PEG chain among the TPGS (molecular weight 1000), easy and cells contacting is also absorbed; And TPGS also has the function that suppresses P-gp, promotes drug absorption and has certain antitumaous effect; TPGS is ratified as pharmaceutic adjuvant by FDA simultaneously, and price is cheap than PEG-DSPE, and its application at liposome will reduce production costs to a great extent.In a word, liposome composition of the present invention and drug-loaded liposome owing to added TPGS, more help bringing into play curative effect of medication.
Description of drawings
Emodin liposome that the emodin liposome that Fig. 1 modifies for PEG-DSPE, TPGS modify and the cytotoxicity figure of free emodin medicine andL1210 cytosis 24h;
Emodin liposome that the emodin liposome that Fig. 2 modifies for PEG-DSPE, TPGS modify and the cytotoxicity figure of free emodin medicine andL1210 cytosis 48h;
Emodin liposome that the emodin liposome that Fig. 3 modifies for PEG-DSPE, TPGS modify and the cytotoxicity figure of free emodin medicine andL1210 cytosis 72h.
The specific embodiment
With specific embodiment technical scheme of the present invention is described further below, but protection scope of the present invention is not limited thereto:
Embodiment 1: the emodin liposome prescription that contains TPGS
Table 1 contains the emodin liposome prescription of TPGS
Formula IFormula I IFormula I IIFormula I V
Prescription mg mg mg mg
EPC 87 65 56 48
Cholesterol 11 24 22 14
TPGS 2 12 22 38
Emodin 5 5 5 5
Lecithin, cholesterol, TPGS and emodin are placed round-bottomed flask, add the ethanol of 15ml and chloroform (2: 8, V/V) mixed solution lipin dissolving and medicine, the decompression rotary evaporation forms thin film, add the normal saline hydrated films and form multilamelar liposome, the ultimate density that makes emodin is 0.5mg/ml.N2Be pressed through 200nm and 100nm polycarbonate membrane down successively, get the single chamber drug-loaded liposome, outward appearance is light yellow turbid shape liquid.
Embodiment 2:PEG-DSPE modifies the comparison of modifying the emodin liposome with TPGS
Respectively the EPC/Chol/TPGS (55/40/5) of identical mol ratio and EPC/Chol/PEG-DSPE (55/40/5) are prepared the emodin liposome by the method for embodiment 1, final emodin concentration is 0.5mg/ml, envelop rate is all more than 90% as a result, about mean diameter 100nm, 4 ℃ of refrigerators were placed 6 months, and stability is all good.Compare the cytotoxicity behind two kinds of liposomees and free emodin and the L1210 cytosis different time, the results are shown in Figure 1-3.From Fig. 1-3 as seen, the emodin liposome of free emodin of the emodin liposome cytotoxicity of TPGS modification and PEG-DSPE modification significantly improves.
Embodiment 2: the amphiphilic alkalescent medicine liposome prescription that contains TPGS
Table 2-1 contains parents' part alkalescent medicine liposome formula I of TPGS
Prescription mg
HSPC 74
Cholesterol 25
TPGS 1
Mitoxantrone hydrochloride 10
Table 2-2 contains the amphiphilic alkalescent medicine liposome formula I I of TPGS
Prescription mg
HSPC 48
Cholesterol 15
TPGS 38
Doxorubicin hydrochloride?7
Table 2-3 contains the amphiphilic alkalescent medicine liposome formula I II of TPGS
Prescription mg
DSPC 81
Cholesterol 17
TPGS 2
Vincristine sulfate 19
Table 2-4 contains the amphiphilic alkalescent medicine liposome formula I V of TPGS
Prescription mg
EPC 56
Cholesterol 22
TPGS 22
Arechin (Polfa) 7
Table 2-5 contains the amphiphilic alkalescent medicine liposome prescription V of TPGS
Prescription mg
DPPC 54
Cholesterol 16
TPGS 30
Daunorubicin hydrochloride 8
Phospholipid, cholesterol and TPGS are dissolved in the ethanol of 1ml, inject 5ml fast and contain 300mM pH4.0 (NH4)2SO4Solution in, form multilamelar liposome, N2Be pressed through 200nm and 100nm polycarbonate membrane down successively, get unilamelar liposome.Reuse contains the (NH in the aqueous solution ultrafiltration displacement liposome disperse medium of 10% sucrose4)2SO4, form the inside and outside NH of liposome bimolecular film4+Gradient gets blank unilamelar liposome, and the lipid total concentration is 20mg/ml, and mean diameter is all less than 100nm.
The above-mentioned Chinese medicine of respectively writing out a prescription is soluble in water, add in the blank unilamelar liposome, 55 ℃ of water-bath 1h, medicine is at NH4+Enter the liposome medicine carrying under the effect of gradient, envelop rate is all more than 90%.
Embodiment 3: the amphiphilic acidic drug liposome prescription that contains TPGS
Table 3-1 contains the amphiphilic acidic drug liposome formula I of TPGS
Prescription mg
HSPC 73
Cholesterol 25
TPGS 2
Prednisolone sodium succinate 7
Table 3-2 contains the amphiphilic acidic drug liposome formula I I of TPGS
Prescription mg
HSPC 55
Cholesterol 23
TPGS 22
Dexamethasone sodium phosphate 10
Phospholipid, cholesterol and TPGS are dissolved in the 1ml ethanol, inject the solution that 5ml contains the 200mM calcium acetate fast, form multilamelar liposome, N2Be pressed through 200nm and 100nm polycarbonate membrane down successively, get unilamelar liposome.Calcium acetate in the reuse 10% sucrose solution dialysis displacement liposome disperse medium forms the inside and outside calcium ion gradient of liposome bimolecular film, gets blank unilamelar liposome, and the lipid total concentration is 20mg/ml, and mean diameter is less than 100nm.
Medicine in the above-mentioned prescription is water-soluble, add in the blank unilamelar liposome that makes, 65 ℃ of water-bath 1h, medicine enter the liposome medicine carrying under the effect of calcium ion gradient, and envelop rate is more than 85%.
Embodiment 4: the water-soluble pesticide composite lipidosome prescription that contains TPGS
Table 4-1 contains the water-soluble pesticide composite lipidosome prescription of TPGS
Prescription mg
HSPC 65
CHEMS 25
TPGS 10
Cisplatin 5
Phospholipid, cholesterol and TPGS are placed round-bottomed flask, add chloroform 15ml lipin dissolving, the decompression rotary evaporation forms thin film, adds cisplatin normal saline hydrated films and forms multilamelar liposome, N2Be pressed through 200nm and 100nm polycarbonate membrane down successively, get the single chamber drug-loaded liposome, the lipid total concentration is 20mg/ml, and mean diameter is less than 100nm, and envelop rate is more than 85%.
Embodiment 5: the hard-soluble medicine liposome prescription that contains TPGS
Table 5-1 contains the hard-soluble medicine liposome formula I of TPGS
Prescription mg
DPPC 69
Cholesterol 11
TPGS 20
Paclitaxel 3.5
Table 4-2 contains the hard-soluble medicine liposome formula I I of TPGS
Prescription mg
?HSPC 58
?DSPG 23
Cholesterol 14
?TPGS 4
Amphotericin B 15
Phospholipid, cholesterol, TPGS and medicine are placed round-bottomed flask, add 15ml ethanol and chloroform (2: 8, V/V) mixed solution lipin dissolving and medicine, the decompression rotary evaporation forms thin film, adds the normal saline hydrated films and forms multilamelar liposome, N2Be pressed through 200nm and 100nm polycarbonate membrane down successively, get the single chamber drug-loaded liposome, the lipid total concentration is 20mg/ml, and mean diameter is less than 100nm, and envelop rate is more than 85%.
Embodiment 6: functional cosmetics liposome prescription
Table 6-1 contains the functional cosmetics liposome formula I of TPGS
Prescription mg
SPC 87
Cholesterol 11
TPGS 2
TheVc cetylate 10
Table 6-2 contains the functional cosmetics liposome formula I I of TPGS
Prescription mg
EPC 85
Cholesterol 5
TPGS 10
Vitamin E acetate 15
Table 6-3 contains the functional cosmetics liposome formula I II of TPGS
Prescription mg
SPC 61
Cholesterol 4
TPGS 34
TheVA cetylate 20
Lecithin, cholesterol, TPGS and medicine are placed round-bottomed flask, add 20ml ethanol and chloroform (3: 7, V/V) mixed solution lipin dissolving and medicine, the decompression rotary evaporation forms thin film, glycerol adding aqueous solution hydrated films forms multilamelar liposome, N2Be pressed through 200nm and 100nm polycarbonate membrane down successively, get the single chamber drug-loaded liposome, the lipid total concentration is 40mg/ml, and mean diameter is less than 100nm, and envelop rate is more than 90%.

Claims (10)

CN2009101016078A2009-08-142009-08-14TPGS-containing liposome composition and application thereofExpired - Fee RelatedCN101991538B (en)

Priority Applications (1)

Application NumberPriority DateFiling DateTitle
CN2009101016078ACN101991538B (en)2009-08-142009-08-14TPGS-containing liposome composition and application thereof

Applications Claiming Priority (1)

Application NumberPriority DateFiling DateTitle
CN2009101016078ACN101991538B (en)2009-08-142009-08-14TPGS-containing liposome composition and application thereof

Publications (2)

Publication NumberPublication Date
CN101991538Atrue CN101991538A (en)2011-03-30
CN101991538B CN101991538B (en)2013-09-11

Family

ID=43782620

Family Applications (1)

Application NumberTitlePriority DateFiling Date
CN2009101016078AExpired - Fee RelatedCN101991538B (en)2009-08-142009-08-14TPGS-containing liposome composition and application thereof

Country Status (1)

CountryLink
CN (1)CN101991538B (en)

Cited By (11)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
WO2014167435A3 (en)*2013-04-102015-02-19Malviya SarveshLiposomal pharmaceutical formulations for enhanced drug delivery
CN104667284A (en)*2015-02-062015-06-03重庆医科大学Application of oleanolic acid in modification of emodin liposome in preparing medicine
CN107811972A (en)*2017-11-032018-03-20华中科技大学A kind of adriamycin and genomic medicine convey nano medicament carrying system and preparation method altogether
CN110981837A (en)*2019-12-032020-04-10沈阳药科大学Paclitaxel weakly acidic derivative active drug-loaded liposome and preparation and application thereof
US10842771B2 (en)2017-11-302020-11-24Shilpa Medicare LimitedComposition of docetaxel liposomal injection with high drug loading
CN113476475A (en)*2021-06-252021-10-08江汉大学Zinc salicylate nanoparticles and preparation method and application thereof
CN114989124A (en)*2022-06-152022-09-02华中科技大学同济医学院附属协和医院 A kind of method for extracting quercetin from Hedyotis diffusa, and preparation method of liposome and liposome product
CN115025292A (en)*2022-06-102022-09-09乐普(北京)医疗器械股份有限公司Drug coating, drug-coated balloon and preparation method thereof
CN115192449A (en)*2021-04-082022-10-18江苏长泰药业有限公司 A kind of method for preparing doxorubicin hydrochloride liposome by microreactor
CN115350290A (en)*2022-10-192022-11-18潍坊中医药产业技术研究院Preparation method and application of resveratrol nanocrystalline liposome based on TPGS modification
CN118948767A (en)*2024-07-242024-11-15洋妆源(北京)网络科技有限公司 A transdermal β-nicotinamide mononucleotide nanoliposome and its preparation method and application

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US11857680B2 (en)2018-11-262024-01-02Shilpa Medicare LimitedComposition of docetaxel liposomal injection with high drug loading

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
GUANGXI ZHAI等: "A Liposomal Delivery Vehicle for the Anticancer Agent Gossypol", 《ANTICANCER RESEARCH》*

Cited By (15)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
WO2014167435A3 (en)*2013-04-102015-02-19Malviya SarveshLiposomal pharmaceutical formulations for enhanced drug delivery
CN104667284A (en)*2015-02-062015-06-03重庆医科大学Application of oleanolic acid in modification of emodin liposome in preparing medicine
CN104667284B (en)*2015-02-062018-02-16重庆医科大学Oleanolic acid is used to modify application of the Emodin Liposome in medicine is prepared
CN107811972A (en)*2017-11-032018-03-20华中科技大学A kind of adriamycin and genomic medicine convey nano medicament carrying system and preparation method altogether
US10842771B2 (en)2017-11-302020-11-24Shilpa Medicare LimitedComposition of docetaxel liposomal injection with high drug loading
CN110981837A (en)*2019-12-032020-04-10沈阳药科大学Paclitaxel weakly acidic derivative active drug-loaded liposome and preparation and application thereof
CN115192449A (en)*2021-04-082022-10-18江苏长泰药业有限公司 A kind of method for preparing doxorubicin hydrochloride liposome by microreactor
CN113476475A (en)*2021-06-252021-10-08江汉大学Zinc salicylate nanoparticles and preparation method and application thereof
CN113476475B (en)*2021-06-252022-11-15江汉大学Zinc salicylate nanoparticles and preparation method and application thereof
CN115025292A (en)*2022-06-102022-09-09乐普(北京)医疗器械股份有限公司Drug coating, drug-coated balloon and preparation method thereof
CN115025292B (en)*2022-06-102023-07-14乐普(北京)医疗器械股份有限公司Drug coating, drug coating balloon and preparation method thereof
CN114989124A (en)*2022-06-152022-09-02华中科技大学同济医学院附属协和医院 A kind of method for extracting quercetin from Hedyotis diffusa, and preparation method of liposome and liposome product
CN115350290A (en)*2022-10-192022-11-18潍坊中医药产业技术研究院Preparation method and application of resveratrol nanocrystalline liposome based on TPGS modification
CN115350290B (en)*2022-10-192022-12-13潍坊中医药产业技术研究院 Preparation method and application of resveratrol nanocrystalline liposomes modified based on TPGS
CN118948767A (en)*2024-07-242024-11-15洋妆源(北京)网络科技有限公司 A transdermal β-nicotinamide mononucleotide nanoliposome and its preparation method and application

Also Published As

Publication numberPublication date
CN101991538B (en)2013-09-11

Similar Documents

PublicationPublication DateTitle
CN101991538A (en)TPGS-containing liposome composition and application thereof
Allahou et al.Investigating the application of liposomes as drug delivery systems for the diagnosis and treatment of cancer
Jadhav et al.Novel vesicular system: an overview
CN100377704C (en)Liposome formulations
JP5645954B2 (en) Irinotecan or its hydrochloride liposome and method for producing the same
CN101485629B (en)Drug delivery system and preparation method thereof
Utreja et al.Novel drug delivery systems for sustained and targeted delivery of anti-cancer drugs: current status and future prospects
TWI362931B (en)Irinotecan formulation
Fidan et al.Recent advances in liposome-based targeted cancer therapy
Liu et al.Effective co-encapsulation of doxorubicin and irinotecan for synergistic therapy using liposomes prepared with triethylammonium sucrose octasulfate as drug trapping agent
CN103479578B (en)The Liposomal formulation of a kind of maleic acid Pixantrone and preparation technology thereof
CN103370055B (en)Long-lasting controlled-release liposome composition and method for producing same
Xiong et al.Preparation, therapeutic efficacy and intratumoral localization of targeted daunorubicin liposomes conjugating folate-PEG-CHEMS
Layek et al.Recent advances in lipid-based nanodrug delivery systems in cancer therapy
CN103120645A (en)Irinotecan or irinotecan hydrochloride lipidosome and preparation method thereof
CN113384530B (en)Polysaccharide core Nanocells and preparation method and application thereof
Pooja et al.Lipid-based nanomedicines: Current clinical status and future perspectives
CN103415283A (en)Liposome formulation comprising an anti-tumour active substance, method for its preparation and pharmaceutical compositions comprising it
WO2015108932A1 (en)Liposome compositions encapsulating modified cyclodextrin complexes and uses thereof
CN102357075A (en)Docetaxel nano preparation and preparation method thereof
Spitler et al.Drug delivery systems: possibilities and challenges
CN101601648B (en)Sub-microemulsion used for intravenous injection of polyene yew alcohol phospholipid composite and preparation method thereof
CN103989624B (en)A kind of irinotecan hydrochloride composition and preparation method thereof
Kumar et al.Novel drug delivery system
CN107708670A (en)Phospholipid-coated therapeutic agent nanoparticles and related methods

Legal Events

DateCodeTitleDescription
C06Publication
PB01Publication
C10Entry into substantive examination
SE01Entry into force of request for substantive examination
C14Grant of patent or utility model
GR01Patent grant
CF01Termination of patent right due to non-payment of annual fee

Granted publication date:20130911

CF01Termination of patent right due to non-payment of annual fee

[8]ページ先頭

©2009-2025 Movatter.jp